Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma

Journal of Neuropathology and Experimental Neurology

Volumn 67, Issue 9, 2008, Pages 878-887

  Bar, Eli E ^a   Lin, Alex ^a   Tihan, Tarik ^b   Burger, Peter C ^a   Eberhart, Charles G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

7q34; BRAF; Comparative genomic hybridization; Pilocytic astrocytoma

Indexed keywords

B RAF KINASE; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 14; PROTEIN KINASE; BRAF PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE;

ADOLESCENT; ADULT; ARTICLE; ASTROCYTOMA; BRAIN TISSUE; CHILD; CHROMOSOME 7Q; CHROMOSOME 7Q34; CHROMOSOME ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA MICROARRAY; ENZYME ACTIVATION; EXON; FEMALE; GENE; GENE FREQUENCY; GENE LOCATION; GENE NUMBER; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; POLYMERASE CHAIN REACTION; POSTERIOR FOSSA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SCHOOL CHILD; TISSUE MICROARRAY; TUMOR LOCALIZATION; WESTERN BLOTTING; BRAIN TUMOR; CHROMOSOME 7; GENE DOSAGE; GENETICS; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; ASTROCYTOMA; BLOTTING, WESTERN; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 7; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAP KINASE KINASE KINASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS B-RAF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS;

EID: 52649172327     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3181845622     Document Type: Article

References (42)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. Lyon, France: IARC Press, 2007
2. Rosemberg S, Fujiwara D. Epidemiology of pediatric tumors of the nervous system according to the WHO 2000 classification: A report of 1,195 cases from a single institution. Childs Nerv Syst 2005;21:940-44
3. Fernandez C, Figarella-Branger D, Girard N, et al. Pilocytic astrocy-tomas in children: Prognostic factorsVa retrospective study of 80 cases. Neurosurgery 2003;53:544-53; discussion 554-45
4. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-89
5. Rorive S, Maris C, Debeir O, et al. Exploring the distinctive biological characteristics of pilocytic and low-grade diffuse astrocytomas using microarray gene expression profiles. J Neuropathol Exp Neurol 2006;65: 794-807
6. Colin C, Baeza N, Bartoli C, et al. Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using suppression subtractive hybridization. Oncogene 2006;25:2818-26
7. Yohay KH. The genetic and molecular pathogenesis of NF1 and NF2. Semin Pediatr Neurol 2006;13:21-26
8. Houshmandi SS, Gutmann DH. All in the family: Using inherited cancer syndromes to understand de-regulated cell signaling in brain tumors. J Cell Biochem 2007;102:811-19
9. Wimmer K, Eckart M, Meyer-Puttlitz B, et al. Mutational and expression analysis of the NF1 gene argues against a role as tumor suppressor in sporadic pilocytic astrocytomas. J Neuropathol Exp Neurol 2002;61: 896-902
10. Platten M, Giordano MJ, Dirven CM, et al. Up-regulation of specific NF 1 gene transcripts in sporadic pilocytic astrocytomas. Am J Pathol 1996; 149:621-27
11. Kluwe L, Hagel C, Tatagiba M, et al. Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J Neuropathol Exp Neurol 2001;60:917-20
12. Zattara-Cannoni H, Gambarelli D, Lena G, et al. Are juvenile pilocytic astrocytomas benign tumors? A cytogenetic study in 24 cases. Cancer Genet Cytogenet 1998;104:157-60
13. Jones DT, Ichimura K, Liu L, et al. Genomic analysis of pilocytic astrocytomas at 0.97 Mb resolution shows an increasing tendency toward chromosomal copy number change with age. J Neuropathol Exp Neurol 2006;65:1049-58
14. Shlomit R, Ayala AG, Michal D, et al. Gains and losses of DNA sequences in childhood brain tumors analyzed by comparative genomic hybridization. Cancer Genet Cytogenet 2000;121:67-72
15. Agamanolis DP, Malone JM. Chromosomal abnormalities in 47 pediatric brain tumors. Cancer Genet Cytogenet 1995;81:125-34
16. Sanoudou D, Tingby O, Ferguson-Smith MA, et al. Analysis of pilocytic astrocytoma by comparative genomic hybridization. Br J Cancer 2000; 82:1218-22
17. Wiltshire RN, Herndon JE, 2nd, Lloyd A, et al. Comparative genomic hybridization analysis of astrocytomas: Prognostic and diagnostic implications. J Mol Diagn 2004;6:166-79
18. Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: C-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004;63:441-49
19. de Smith AJ, Tsalenko A, Sampas N, et al. Array CGH analysis of copy number variation identifies 1284 new genes variant in healthy white males: Implications for association studies of complex diseases. Hum Mol Genet 2007;16:2783-94
20. Konigshoff M, Wilhelm J, Bohle RM, et al. HER-2/neu gene copy number quantified by real-time PCR: Comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissue. Clin Chem 2003;49:219-29
21. Eberhart CG, Kratz JE, Schuster A, et al. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 2002;12:36-44
22. Pfister S, Janzarik WG, Remke M, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008;118:1739-49
23. Deshmukh H, Yeh TH, Yu J, et al. High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene 2008. [Epub ahead of print]
24. Dhomen N, Marais R. New insight into BRAF mutations in cancer. Curr Opin Genet Dev 2007;17:31-39
25. Houben R, Vetter-Kauczok CS, Ortmann S, et al. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. J Invest Dermatol 2008. [Epub ahead of print]
26. Kondo T, Nakazawa T, Murata S, et al. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum Pathol 2007;38:1810-18
27. Brunet A, Roux D, Lenormand P, et al. Nuclear translocation of p42/p44 mitogenactivated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J 1999;18:664-74
28. White FV, Anthony DC, Yunis EJ, et al. Nonrandom chromosomal gains in pilocytic astrocytomas of childhood. Hum Pathol 1995;26: 979-86
29. Wemmert S, Romeike BF, Ketter R, et al. Intratumoral genetic heterogeneity in pilocytic astrocytomas revealed by CGH-analysis of microdissected tumor cells and FISH on tumor tissue sections. Int J Oncol 2006;28:353-60
30. Sharma MK, Zehnbauer BA, Watson MA, et al. RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology 2005;65:1335-36
31. Janzarik WG, Kratz CP, Loges NT, et al. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics 2007;38: 61-63
32. Yu J, Zhang H, Gu J, et al. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 2004;4:65
33. Jeuken J, van den Broecke C, Gijsen S, et al. RAS/RAF pathway activation in gliomas: The result of copy number gains rather than activating mutations. Acta Neuropathol 2007;114:121-33
34. Michaloglou C, Vredeveld LC, Mooi WJ, et al. BRAF(E600) in benign and malignant human tumours. Oncogene 2008;27:877-95
35. Chong H, Guan KL. Regulation of Raf through phosphorylation and N-terminus-C terminus interaction. J Biol Chem 2003;278:36269-76
36. Heidecker G, Huleihel M, Cleveland JL, et al. Mutational activation of c-raf-1 and definition of the minimal transforming sequence. Mol Cell Biol 1990;10:2503-12
37. Dessars B, De Raeve LE, El Housni H, et al. Chromosomal trans-locations as a mechanism of BRAF activation in two cases of large congenital melanocytic nevi. J Invest Dermatol 2007;127: 1468-70
38. Jones DT, Kocialkowski S, Liu L, et al. A novel oncogenic fusion gene is found in the majority of pilocytic astrocytomas. In: 2008 Annual Meeting of the American Association for Cancer Research. San Diego, CA; 2008
39. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007;120:3163-72
40. Espinosa AV, Porchia L, Ringel MD. Targeting BRAF in thyroid cancer. Br J Cancer 2007;96:16-20
41. Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol 2008;20:183-89
42. Ball DW, Jin N, Rosen DM, et al. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogenactivated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab 2007;92:4712-18